Results of letrozole in postmenopausal women after tamoxifen treatment for advanced breast cancer.

Simple item page
dc.contributor.authorYadav, B Sen_US
dc.contributor.authorSharma, S Cen_US
dc.contributor.authorPatel, F Den_US
dc.contributor.authorGhoshal, Sen_US
dc.contributor.authorKapoor, Ven_US
dc.date.accessioned2007-04-14en_US
dc.date.accessioned2009-06-01T16:23:23Z
dc.date.available2007-04-14en_US
dc.date.available2009-06-01T16:23:23Z
dc.date.issued2007-04-14en_US
dc.description.abstractAIM: To analyze overall and progression-free survival after letrozole in postmenopausal women with advanced breast cancer who failed after tamoxifen therapy. MATERIALS AND METHODS: This is a retrospective analysis of 95 patients with breast cancer who were postmenopausal and had failed after tamoxifen therapy. Dose of letrozole was 2.5 mg daily until disease progressed. Patients had estrogen receptor- and/or progesterone receptor-positive tumors or both receptors were unknown. One complete course of (6 cycles) chemotherapy for metastatic disease was allowed. The primary end point was time to progression (TTP). Secondary end points included overall objective response rate (ORR), its duration, time to treatment failure (TTF), overall survival and tolerability. RESULTS: Median TTP was 10 months. ORR was 21% with complete response rate of 9%. Nine patients died of disease during treatment. Median overall survival was 36 months. Median time to response was three months and median duration of response was 13 months. Time to chemotherapy was 13.5 months and TTF was 9.3 months. Treatment failure was seen in 76% of patients. Disease progression was the main cause for treatment failure. Treatment was well-tolerated by all patients. CONCLUSION: This retrospective analysis shows that letrozole is quite effective as second line therapy in postmenopausal patients with advanced breast cancer who had failed after tamoxifen therapy.en_US
dc.description.affiliationDept. of Radiotherapy, Postgraduate Institute of Medical Education and Research, Chandigarh-160 012, India. drbudhi@gmail.comen_US
dc.identifier.citationYadav BS, Sharma SC, Patel FD, Ghoshal S, Kapoor V. Results of letrozole in postmenopausal women after tamoxifen treatment for advanced breast cancer. Journal of Cancer Research and Therapeutics. 2007 Apr-Jun; 3(2): 71-4en_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/111516
dc.language.isoengen_US
dc.source.urihttps://www.cancerjournal.neten_US
dc.subject.meshAdulten_US
dc.subject.meshAgeden_US
dc.subject.meshAntineoplastic Agents --adverse effectsen_US
dc.subject.meshAromatase Inhibitors --adverse effectsen_US
dc.subject.meshBreast Neoplasms --drug therapyen_US
dc.subject.meshFemaleen_US
dc.subject.meshHumansen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshNitriles --adverse effectsen_US
dc.subject.meshPostmenopauseen_US
dc.subject.meshRetrospective Studiesen_US
dc.subject.meshTamoxifen --therapeutic useen_US
dc.subject.meshTreatment Outcomeen_US
dc.subject.meshTriazoles --adverse effectsen_US
dc.titleResults of letrozole in postmenopausal women after tamoxifen treatment for advanced breast cancer.en_US
dc.typeJournal Articleen_US
Files
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.79 KB
Format:
Plain Text
Description:
Download
Collections
Journal of Cancer Research and Therapeutics